Allogene Therapeutics (NASDAQ: ALLO) is one of 275 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Allogene Therapeutics to related businesses based on the strength of its dividends, risk, analyst recommendations, valuation, earnings, profitability and institutional ownership.
This is a summary of recent recommendations for Allogene Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Allogene Therapeutics Competitors||492||1820||4788||117||2.63|
Earnings & Valuation
This table compares Allogene Therapeutics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Allogene Therapeutics Competitors||$93.78 million||-$44.17 million||-19.19|
Allogene Therapeutics’ competitors have higher revenue, but lower earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
44.9% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Biotechnology” companies are owned by institutional investors. 19.8% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Allogene Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Allogene Therapeutics Competitors||-3,871.53%||-175.04%||-40.52%|
Allogene Therapeutics beats its competitors on 7 of the 11 factors compared.
About Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.